BioLineRx to Present at the 2014 BIO CEO & Investor Conference in New York on February 10
A live webcast of the presentation will be available on BioLineRx's website. A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.
Investors or potential partners attending the conference, who wish to meet with Dr. Savitsky or Mr. Serlin, should contact the BIO Partnering Team at firstname.lastname@example.org.
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in
BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to
For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's